Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer

Published on 27 Jul 2021
Last Updated on 17 Aug 2021

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Dacomitinib 15 mg, 30 mg and 45 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer.

Subsidy status

Dacomitinib 15 mg, 30 mg and 45 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) with effect from 3 August 2021.

Dacomitinib for treating EGFR mutation-positive NSCLC (17 Aug 2021) [PDF, 142 KB]

Dacomitinib for treating EGFR mutation-positive NSCLC PES (27 Jul 2021) [PDF, 73 KB]